When Your Pharmacogenomics Test and Your Oncologist’s Prescription Don’t Match: What Should a Cancer Patient Do?

Precision medicine is transforming cancer care. Many cancer patients today undergo pharmacogenomics (PGx) testing, which analyzes how genetic variations influence the way a person metabolizes and responds to medications. These tests can help predict whether a drug may be less effective, require dose adjustment, or carry a higher risk of side effects.

However, some patients experience confusion when their pharmacogenomics report appears to contradict the medication prescribed by their oncologist. This situation can be unsettling, but it is not uncommon—and it does not necessarily mean that something has gone wrong.

Understanding why these differences occur can help patients make informed decisions about their treatment.

Why Pharmacogenomics Results May Appear to Contradict Prescribed Drugs

1. Pharmacogenomics Is Only One Piece of the Clinical Decision

Cancer treatment decisions are complex. Oncologists must consider multiple factors simultaneously, including:

• The type and stage of cancer

• Tumor genomic mutations

• Evidence from clinical trials and treatment guidelines

• The patient’s overall health and comorbidities

• Previous treatment responses

Pharmacogenomics focuses primarily on how the body processes a drug, not whether the drug will work against the tumor itself. Therefore, an oncologist may still prescribe a medication if its anti-cancer benefits outweigh the potential pharmacogenomic risks, while adjusting the dose or monitoring closely.

2. Many PGx Results Indicate Dose Adjustment, Not Drug Avoidance

Not all pharmacogenomic findings mean a drug should be avoided.

For example, PGx reports may indicate:

• Normal metabolism – standard dosing

• Intermediate metabolism – possible dose adjustment

• Poor metabolism – increased risk of toxicity

• Ultra-rapid metabolism – reduced drug effectiveness

In many cases, guidelines such as those from CPIC (Clinical Pharmacogenetics Implementation Consortium) recommend dose modification rather than eliminating the drug entirely.

Your oncologist may therefore continue prescribing the medication while modifying the dosage.

3. Oncology Drugs Often Have Different Clinical Priorities

In oncology, treatment urgency can be high. Some drugs are considered standard-of-care therapies with strong survival benefits.

Even when pharmacogenomic variants suggest a higher risk of side effects, clinicians may proceed because:

• The expected clinical benefit is substantial

• Alternative treatments may be less effective

• Side effects can be managed or monitored

In these cases, the oncologist may prioritize tumor control while carefully managing toxicity risks.

4. Not All PGx Tests Use the Same Evidence Standards

Another important factor is how the pharmacogenomics test was designed.

Different PGx tests may vary in:

• The number of genes analyzed

• The variants included

• The interpretation database used

• The clinical guideline references applied

Some reports may rely heavily on research findings, while others follow internationally accepted guidelines such as:

• CPIC

• PharmGKB

• FDA pharmacogenomic labeling

• DPWG (Dutch Pharmacogenetics Working Group)

If the report is based on different interpretation criteria, it may produce recommendations that appear inconsistent with clinical practice guidelines.

5. Tumor Genomics and Pharmacogenomics Are Different Tests

Cancer patients often undergo two distinct types of genomic testing:

1. Tumor genomic testing (somatic mutations)Identifies mutations in cancer cells that guide targeted therapy.

2. Pharmacogenomics testing (germline genetics)Evaluates inherited genes affecting drug metabolism.

A drug may be strongly recommended based on tumor genetics, even if PGx testing suggests careful dosing.

What Should Cancer Patients Do If There Is a Discrepancy?

If your pharmacogenomics report appears to contradict your oncologist’s prescription, the most important step is not to panic or stop medication on your own.

Instead, consider the following actions:

1. Discuss the PGx Report with Your Oncologist

Bring the report to your doctor and ask:

• Whether the PGx result affects dose selection

• Whether alternative drugs exist

• Whether additional monitoring is needed

Most oncologists appreciate pharmacogenomic information when it is presented in the proper clinical context.

2. Request a Pharmacogenomics or Genetic Counseling Review

PGx reports can sometimes be misinterpreted outside clinical context. A qualified professional can help interpret:

• Gene–drug interactions

• Guideline-based recommendations

• Clinical relevance to your treatment plan

3. Ensure the Test Meets Clinical Quality Standards

Reliable pharmacogenomics testing should be performed in laboratories that meet international quality standards such as:

• ISO 15189 medical laboratory accreditation

• CAP accreditation

• Participation in international External Quality Assessment (EQA) programs

These quality systems ensure that results are technically accurate and clinically validated.

4. Consider Integrating PGx Results into Long-Term Medication Planning

Even if a specific oncology drug is necessary today, PGx results can still be extremely valuable for other medications, including:

• Pain management

• Antidepressants

• Anticoagulants

• Anti-nausea drugs

• Supportive cancer therapies

Pharmacogenomics can therefore help optimize overall treatment safety throughout the cancer journey.

The Key Message: Pharmacogenomics Supports—But Does Not Replace—Clinical Judgment

Pharmacogenomics is a powerful tool in precision medicine, but it does not replace clinical expertise. Instead, it provides an additional layer of information that helps physicians make safer and more personalized treatment decisions.

When interpreted correctly and combined with clinical judgment, PGx testing can help reduce adverse drug reactions, improve treatment tolerability, and guide better medication choices.

For cancer patients, the best approach is collaboration between oncologists, pharmacogenomics specialists, and the patient to ensure that genomic insights translate into the most effective and safest treatment strategy.

---

Integrating Pharmacogenomics and Tumor Genomics for Safer Cancer Treatment

At AGTC Genomics, precision oncology goes beyond pharmacogenomics alone. Our PharmPGx™ Comprehensive Pharmacogenomics Test analyzes clinically relevant pharmacogenes using next-generation sequencing and evidence-based interpretation aligned with international pharmacogenomics guidelines, helping clinicians anticipate how a patient may metabolize and respond to medications.

In addition, we provide OncoDx™ Comprehensive Gene Profiling, which analyzes tumor tissue to identify actionable cancer mutations and guide targeted therapy selection, as well as LiquidDx™ ctDNA Liquid Biopsy, a minimally invasive blood test that detects circulating tumor DNA to profile cancer mutations and monitor treatment response.

By integrating pharmacogenomics (how the body processes drugs) with tumor genomic profiling (what drives the cancer), clinicians gain a more complete picture to optimize treatment strategies, anticipate potential side effects, and improve therapeutic outcomes.

All tests are performed in our ISO 15189 and CAP-accredited advanced genomics laboratory, supported by experienced bioinformaticians, pharmacists, and genomic specialists to ensure clinically meaningful interpretation.

If you would like to understand how integrated genomic testing may support safer and more personalized cancer treatment, speak to your healthcare provider or consult AGTC Genomics to learn more about PharmPGx™, OncoDx™, and LiquidDx™ testing available through selected hospitals, clinics, and partner healthcare providers nationwide.